Relapsed/Refractory CLL: Practical Advice and Future Directions in Care
A key opinion leader on relapsed/refractory chronic lymphocytic leukemia provides practical advice on patient management and looks toward future evolutions in the treatment landscape.
Relapsed/Refractory CLL: CV Safety Data With Available Therapies
Comprehensive insight to cardiovascular safety data with available therapies and how current understandings may impact the management of patients with relapsed/refractory chronic lymphocytic leukemia.
Role of Efficacy Data in Selecting Optimal Therapy for Patients With Relapsed/Refractory CLL
Centering conversation on patients with relapsed/refractory chronic lymphocytic leukemia, Andrew Lipsky, MD, reviews efficacy data and considers how it impacts treatment selection.
Clinical Trial Data in Relapsed/Refractory CLL: The ELEVATE-RR Trial
Shared insight on ELEVATE-RR, which utilized acalabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Clinical Trial Data in Relapsed/Refractory CLL: The ALPINE Trial
Expert perspectives on the ALPINE trial of zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Role of BTK Inhibitors as Second-Line Therapy for Patients With CLL
Andrew Lipsky, MD, considers the role of BTK inhibitors as second-line therapy in patients with relapsed/refractory chronic lymphocytic leukemia.
Chronic Lymphocytic Leukemia: First-Line Treatment Armamentarium
Focused discussion on the first-line treatment armamentarium available to patients diagnosed with chronic lymphocytic leukemia.
Case Overview: Relapsed/Refractory CLL Treated With a BTK Inhibitor
Expert Andrew Lipsky, MD, reviews a patient case of relapsed/refractory chronic lymphocytic leukemia managed with BTK inhibition in the second-line setting.
